AC Immune SA (NASDAQ:ACIU) Short Interest Up 23.5% in October

AC Immune SA (NASDAQ:ACIU) saw a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 984,500 shares, an increase of 23.5% from the October 15th total of 796,900 shares. Based on an average daily volume of 92,100 shares, the short-interest ratio is presently 10.7 days. Approximately 1.6% of the shares of the company are sold short.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on ACIU. StockNews.com downgraded AC Immune from a “buy” rating to a “hold” rating in a research note on Tuesday, October 1st. HC Wainwright reissued a “buy” rating and issued a $16.00 target price on shares of AC Immune in a report on Wednesday, November 6th.

Institutional Investors Weigh In On AC Immune

A number of hedge funds have recently modified their holdings of the business. Lazard Asset Management LLC purchased a new position in AC Immune during the first quarter valued at $30,000. BNP Paribas Financial Markets raised its stake in shares of AC Immune by 315.6% in the first quarter. BNP Paribas Financial Markets now owns 11,092 shares of the company’s stock worth $33,000 after buying an additional 8,423 shares during the period. Silverberg Bernstein Capital Management LLC purchased a new position in shares of AC Immune during the 2nd quarter valued at about $40,000. Vanguard Capital Wealth Advisors bought a new position in shares of AC Immune during the 2nd quarter valued at approximately $56,000. Finally, China Universal Asset Management Co. Ltd. increased its holdings in AC Immune by 63.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 19,021 shares of the company’s stock worth $72,000 after acquiring an additional 7,400 shares in the last quarter. Institutional investors own 51.36% of the company’s stock.

AC Immune Trading Up 13.4 %

Shares of ACIU stock opened at $3.55 on Friday. AC Immune has a 12 month low of $2.25 and a 12 month high of $5.14. The stock has a market cap of $351.24 million, a P/E ratio of -7.72 and a beta of 1.28. The company has a 50 day simple moving average of $3.27 and a two-hundred day simple moving average of $3.47.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.